Synthetic biology companies are to receive £5.3 million from the Technology Strategy Board, the Biotechnology and Biological Sciences Research Council, and the Engineering and Physical Sciences Research Council.
Announced on 7 March, the grants will fund 15 projects to explore the feasibility of synthetic biology for producing novel or improved products and processes.
The grants were given to business-led collaborations, with leading companies including Cambimmune in Cambridge, Synthace in London, Oxitec in Oxford and Unilever in Bedford.
This article on Research Professional News is only available to Research Professional or Pivot-RP users.
Research Professional users can log in and view the article via this link
Pivot-RP users can log in and view the article via this link.